A
MLYS icon

AlphaQuest’s Mineralys Therapeutics MLYS Stock Holding History

AlphaQuest’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,328
Closed -$411K – 1244
2025
Q4 		$411K Sell
11,328
-1,277
-10% -$51.2K 0.02% 972
2025
Q3 		$478K Sell
12,605
-2,236
-15% -$48.4K 0.03% 819
2025
Q2 		$201K Sell
14,841
-1,084
-7% -$15.7K 0.02% 1129
2025
Q1 		$253K Buy
15,925
+703
+5% +$8.09K 0.03% 872
2024
Q4 		$187K Buy
15,222
+14,666
+2,638% +$192K 0.02% 884
2024
Q3 		$6.73K Buy
+556
New +$6.73K ﹤0.01% 1570

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

AlphaQuest's MLYS Position: Q1 2026 in Review

AlphaQuest sold out of Mineralys Therapeutics (MLYS) in Q1 2026, closing a stake of 11,328 shares — an estimated $411K sold.

AlphaQuest first reported a position in MLYS in Q3 2024 and held it in 6 quarters. The position peaked at $478K in Q3 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • AlphaQuest reported no remaining Mineralys Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 11,328 Mineralys Therapeutics shares in Q1 2026, an estimated $411K.
  • AlphaQuest first reported a position in Mineralys Therapeutics in Q3 2024 and held it in 6 quarters.
  • AlphaQuest's Mineralys Therapeutics position peaked at $478K in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.